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Abstract: Vitamin B12 (cobalamin) is an essential cofactor in the one-carbon metabolism. One-carbon
metabolism is a set of complex biochemical reactions, through which methyl groups are utilised or
generated, and thus plays a vital role to many cellular functions in humans. Low levels of cobalamin
have been associated to metabolic/reproductive pathologies. However, cobalamin status has never
been investigated in morbid obesity in relation with the reduced semen quality. We analysed the
cross-sectional data of 47-morbidly-obese and 21 lean men at Careggi University Hospital and
evaluated total cobalamin (CBL) and holotranscobalamin (the active form of B12; holoTC) levels in
serum and semen. Both seminal and serum concentrations of holoTC and CBL were lower in morbidly
obese compared to lean men, although the difference did not reach any statistical significance for
serum holoTC. Seminal CBL and holoTC were significantly higher than serum levels in both groups.
Significant positive correlations were observed between seminal holoTC and total sperm motility
(r = 0.394, p = 0.012), sperm concentration (r = 0.401, p = 0.009), total sperm number (r = 0.343,
p = 0.028), and negative correlation with semen pH (r = −0.535, p = 0.0001). ROC analysis supported
seminal holoTC as the best predictor of sperm number (AUC = 0.769 ± 0.08, p = 0.006). Our findings
suggest that seminal rather than serum levels of holoTC may represent a good marker of semen
quality in morbidly obese subjects.
Keywords: active vitamin B12; cobalamin; morbid obesity; body mass index; sperm; seminal plasma
1. Introduction
B12 (cobalamin, CBL) is a water-soluble vitamin synthesized only in bacteria [1]. Humans
require an external source of this vitamin, primarily through dietary intake or from pharmacological
supplementation, as it cannot be absorbed from the intestinal microbiota production [2]. This
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vitamin is crucial for homeostasis and growth as it acts as a coenzyme for the synthesis of
methionine, a precursor of S-adenosyl methionine which provides the methyl groups for the
methylation processes of macromolecules such as DNA, lipids, proteins, and neurotransmitters
acting in the one-carbon-metabolism [3,4]. Around 10%–30% of circulating CBL is bound to the
carrier transcobalamin in a complex named holotranscobalamin (holoTC), which is considered the
bioactive vitamin B12 [5]. HoloTC has been proposed to represent a better marker than CBL of the
vitamin deficiency status [6–8]. Another metabolic marker inversely associated with cobalamin is
methylmalonic acid used to detect CBL deficiency at tissue levels [6], however, it is not routinely
available for clinical testing.
Data present in the literature supports an association between CBL serum concentrations and
metabolic pathologies, including obesity. Morbidly obese subjects [9–11] and patients with insulin
resistance [12] present low concentrations of serum CBL. A positive association between CBL and
dyslipidemia was found in two ethnic groups with type 2 diabetes (T2D) [13]. Similarly, an association
was described between CBL and lower cord blood HDL in White Europeans [14]. A recent systemic
review failed to establish any inverse association between circulating CBL and body mass index
(BMI) when considering studies including not only obese but also underweight subjects [12]: this
relation resulted in a J-shaped association. However, the very large heterogeneity in the meta-analyses
considered in that study might have significantly affected the results [12]. Moreover, folate and age
but not circulating CBL remained independently associated with the number of metabolic syndrome
components in a large cohort of morbidly obese subjects following multivariate analysis [12]. Finally, the
very recent analysis of the data from the nationwide population-based study in the U.S (National Health
and Nutrition Examination Survey, NHANES), demonstrated the association of serum cobalamin with
obesity by showing that those individuals with higher serum cobalamin levels were less likely to be
obese [15].
It is known that morbid obesity is associated with sub-fertility [16–19], reduced semen
quality [19–22], impaired sperm acrosome reaction [23], and sperm fatty acid composition and
functions [24,25]. In particular, a large population study performed in men (n = 4,860), classified
according to their BMI (underweight: n = 45, normal weight: n = 1,330, overweight: n = 2,493, obese:
n = 926, and morbidly obese: n = 57), has shown that at both extremes of BMI (underweight and
morbidly obese subjects), semen parameters were significantly worse and associated with lower sperm
epididymal maturation compared to the other BMI classes [22]. Similar results have been found in
a recent observational study conducted on 3,966 sperm donors in China for the underweight and
overweight classes, but not for the obese class [26]. This may be due to enrolment bias (sperm donor
bank) and the involvement of a small percentage of obese men (0.9%) (see also [19]).
Conflicting data is still present in the literature about the relation between low circulating CBL
and male infertility [27–29]. However, a strong correlation was found between seminal CBL and sperm
concentrations in a cohort of couples undergoing assisted reproductive techniques for infertility [30].
Altered absorption of CBL has been described in morbid obesity [9], however CBL and holoTC in
serum and semen of these subjects have never been investigated and related to semen quality.
Therefore, the aim of the present cross-sectional observational study was to investigate the possible
relationship between holoTC/CBL status and semen quality in a cohort of 47 morbidly obese versus 21
lean men. In particular, we compared holoTC versus CBL concentrations in serum and semen, and
analysed their relationship with seminal parameters with no aim to use them for the diagnosis of
vitamin deficiency.
2. Materials and Methods
2.1. Patients
Morbidly obese men who were on the waiting list for bariatric surgery at the Bariatric Unit of
Careggi University Hospital in Florence (AOUC) were recruited to the proposed study. Any bias
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with infertility was avoided as the morbidly obese patients were not recruited in andrology centres.
Inclusion criteria: BMI ≥ 38 Kg/m2, age between 20 and 65 years. Exclusion criteria: restrictive diet
regimen, gastric balloon insertion, previous bariatric intervention, vitamin B12 supplementation, and
tumour pathologies. A standard non-restrictive balanced diet had been prescribed to all patients by
the Unit’s dieticians. Lean men were enrolled among subjects undergoing routine semen analysis for
couple infertility at the Andrology Unit at AOUC. Inclusion criteria: 18.5 Kg/m2 ≤ BMI < 25 Kg/m2,
age between 20 and 65 years. Exclusion criteria: couple infertility due to male factor, restrictive diet
regimen, vitamin B12 supplementation, and tumour pathologies. The study was approved by the Local
Ethical Committee and Institutional Review Board (approval protocol number 83/13 of 10.25.2003). All
patients provided signed informed consent after receiving written and oral information on the study.
2.2. Biochemical and Anthropometric Measurements
1) Anthropometric measures: Height, weight, and waist circumference were measured in each
subject and blood was drawn in the morning before seminal analysis.
2) Vitamin B12: CBL and holoTC concentrations were measured in frozen serum and semen samples
using the respective competitive and chemiluminescent enzyme immunoassays (ADVIA Centaur
B12 and ADVIA Centaur Active-B12 Assays, Siemens Healthcare, Milan, Italy) based on LOCI
technology on the Dimension Vista System (Siemens). Before holoTC determination, semen
samples were diluted (1:3) with Multi-Diluent 13 (Siemens), centrifuged at 2,700g for 10 minutes
and the supernatant was analysed. CBL and holoTC concentrations were expressed in pmol/L.
3) Biochemical and sex steroid hormones: Glycated haemoglobin (HbA1c) was measured on the
whole-blood samples by high-performance liquid chromatography ion exchange chromatography
on a VARIANT II instrument (Biorad Laboratories, Milan, Italy). HbA1c values were used
for the diagnosis of T2D at the 6.5% threshold. Serum levels of total testosterone (TT),
sex-hormone-binding-globulin (SHBG), estradiol (E2), and the gonadotropin follicle-stimulating
hormone (FSH) and luteinizing hormone (LH) were measured by immunoassay (Immulite 2000,
M-Medical System, Italy); assay analytical sensitivity: 0.5 nM (TT), 55 pM (E2), 0.02 nM (SHBG),
20.1 mIU/ml (FSH) and 0.05 mIU/ml (LH). Free testosterone (cFT) was calculated on SHBG and
TT, as previously described [31].
2.3. Semen Analysis
Human semen was obtained by masturbation according to the World Health Organization
procedure [32] together with a blood sample on the same day or within one week. Semen parameters
were analysed by a routine procedure [21,32]. Briefly, sperm morphology and motility were assessed
by optical microscopy. Sperm morphology was evaluated as the percentage of normal and abnormal
forms with Diff-Quick staining, scoring at least 100 spermatozoa/slide. Sperm motility was reported as
the percentage of progressive motile, non-progressive motile, and immotile spermatozoa on at least
200 sperm/slide, total sperm motility was defined as progressive and non-progressive motile [21].
2.4. Statistical Analysis
Data was expressed as mean ± SD and as median (interquartile range, IQR) for normally and
not-normally distributed parameters, respectively. All statistical analyses were performed on SPSS
24.0 for Windows (Statistical Package for the Social Sciences, Chicago, USA). Kolmogoroff–Smirnov’s
test was used to determine the parametric distribution of data. CBL and holoTC data and most
of the seminal parameters had a not-normally distributed distribution, while BMI, weight, and
waist circumference were normally distributed. The Mann–Whitney U test was used for comparing
two groups of not-normally distributed data, while the two-tailed Student’s t-test was applied for
comparison of normally distributed data. Correlations were assessed using Spearman’s method for
not-normally distributed parameters. ROC analysis was performed to evaluate accuracy, as well as
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sensitivity and specificity of the assessment of semen and serum holoTC and CBL concentrations in
predicting semen quality. A p < 0.05 value was used for statistical significance.
3. Results
Anthropometric characteristics of morbidly obese and lean patients are reported in Table 1, along
with the circulating levels of sex steroid hormones (TT, fT, E2, FSH, and LH), SHBG, and HbA1c.
The prevalence of hypogonadism (TT < 12 nM) [33] and T2D (HbA1c ≥ 6.5%) was 66% and 28% in
the morbidly obese cohort, while 22% and 0% in the lean cohort, respectively. Smokers and alcohol
consumers are reported as percentages (Table 1).
Table 1. Biochemical and anthropometric characteristics of the patients: Anthropometric data and
circulating levels of sex steroid hormones, SHBG and HbA1c are reported along with the prevalence
of hypogonadism (TT < 12 nM), T2D (HbA1c ≥ 6.5), smokers (at least 1 cigarette/day), and alcohol
consumers (at least 2 drinks/day) in each cohort. Data was normally distributed and reported as mean
± SD. Two-tailed Student’s t-test p values for comparison between obese and lean subjects are shown;
χ2 was applied for comparison of non-continuous parameters (hypogonadism, T2D, smokers, alcohol
consumers). Significant p values are indicated in italics.
Morbidly Obese
n = 47
Lean
n = 21 p
Age (years) 42.0 ± 11.6 38.4 ± 7.9 0.207
BMI (Kg/m2) 46.5 ± 7.7 25.2 ± 3.9 0.0001
Weight (Kg) 149.5 ± 26.6 79.1 ± 10.0 0.0001
WC (cm) 142.7 ± 18.5 96.6 ± 4.0 0.0001
FSH (mIU/L) 4.47 ± 2.88 4.10 ± 1.47 0.740
LH (mIU/L) 2.98 ± 1.93 3.21 ± 1.86 0.757
TT (nM) 9.19 ± 4.31 14.44 ± 6.39 0.005
fT (nM) 0.219 ± 0.104 0.319 ± 0.104 0.015
E2 (pM) 139.2 ± 53.4 101.8 ± 35.2 0.024
SHBG (nM) 23.0 ± 9.8 28.3 ± 10.5 0.168
HbA1c (%) 6.2 ± 1.2 4.8 ± 0.3 0.0001
Hypogonadism (%) 66 22 0.029
T2D (%) 28 0 0.045
Smokers (%) 16 19 0.786
Alcohol consumers (%) 21 15 0.567
BMI: body mass index; WC: waist circumference; FSH: follicle stimulating hormone; LH: luteinizing hormone;
TT: testosterone; fT: free-testosterone; T2D: type 2 diabetes.
CBL and holoTC concentrations were measured in the serum and semen of morbidly obese and
lean subjects as shown in Table 2. CBL immunoassay had an analytical sensitivity of 37 pmol/L [34].
According to our measurements, the intra-assay and inter-assay coefficients of variation (CV%) in
serum were 3.38 and 4.37 respectively, while in semen the values were 1.73 and 2.15, respectively. The
values of analytical accuracy were evaluated according to CLSI EP05-A3 [35].
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Table 2. CBL and holoTC concentrations in serum and semen: HoloTC and CBL concentrations are
reported for morbidly obese and lean subjects as median (IQR) for not-normally distributed parameters
and the Mann–Whitney U test was applied for comparison between obese and lean subjects. Statistical
significance between seminal and circulating concentrations of holoTC and CBL: Significant p values
are indicated in italics for comparison between morbidly obese and lean subjects.
Morbidly Obese
n = 47
Lean
n = 21
p
Mann–Whitney U
Serum concentrations
holoTC (pmol/L) 64.5 (51.7) 95.1 (52.1) 0.780
CBL (pmol/L) 233.5 (99.2) 328.0 (259.0) 0.012
Semen concentrations
holoTC (pmol/L) 83.9 (95.1) * 148.3 (67.0) * 0.025
CBL (pmol/L) 811.3 (477.0) ** 1074 (456.0) ** 0.006
CBL: cobalamin; holoTC: holotranscobalamin; * p < 0.005 and ** p < 0.001.
The ADVIA Centaur AB12 assay for holoTC in serum had the Limit of Detection (LOD) of
1.08 pmol/L and the Limit of Quantification (LOQ) of 5.00 pmol/L, determined as described in the CLSI
documentation EP17-A2 [36]. The linearity was maintained for values 5.00–146.00 pmol/L, evaluated
according to the protocol CLSI EP6-A [37]. According to our measurements, the intra-assay and
inter-assay repeatability CVs% obtained in serum were 2.38 and 4.36 respectively, and in semen, 3.11
and 4.36, respectively.
CBL deficiency, defined as <148 pmol/L serum concentrations [38], was present in 8% of the
morbidly obese men and not in the lean cohort.
HoloTC strongly correlated with CBL in both semen and serum in the whole population
(Figure 1A,B). Conversely, only holoTC significantly correlated between semen and serum (r = 0.538,
r2 = 0.290, P = 0.014), while CBL did not.
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Figure 1. Positive correlations between CBL and holoTC concentrations in semen (A) and serum (B) 
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significant correlations were found between holoTC/CBL and BMI, weight, waist circumference 
(WC), sex steroid hormones, and HbA1c.  
Figure 1. Positive correlations between CBL and holoTC concentrations in semen (A) and serum
(B) in all subjects. Correlations were evaluated by Spearman’s test for not-normally distributed
data in a univariate analysis: r, r2, and p from linear regression are indicated. CBL: cobalamin;
holoTC: holotranscobalamin.
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In both cohorts, CBL and holoTC concentrations were significantly higher in semen versus serum
samples (CBL: P < 0.001, and holoTC: P < 0.005, Table 2, Figure 2). Morbidly obese subjects presented
significantly lower concentrations of both CBL (p = 0.006) and holoTC (p = 0.025) in semen compared
to lean subjects (Table 1, Figure 2), while the differences between the two cohorts reached a statistical
significance in the serum for CBL only (p = 0.012, Table 1, Figure 2). Not-statistically significant
correlations were found between holoTC/CBL and BMI, weight, waist circumference (WC), sex steroid
hormones, and HbA1c.Nutrients 2019, 11, x FOR PEER REVIEW 6 of 14 
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Figure 2. CBL and holoTC concentrations in serum and seminal samples from morbidly obese and
lean subjects. Data is not-normally distributed and reported as box charts for holoTC (A) and CBL
(B) serum and semen concentrations; p derived from the Mann-Whitney U test analysis is indicated.
MOB: morbidly obese subjects; LEAN: lean subjects.
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The quality of seminal parameters was significantly reduced in the morbidly obese cohort compared
to the lean subjects, in particular when considering total sperm motility, vitality, concentration, and
total number, as well as semen volume and pH (Table 3). In order to investigate the relationship
between CBL and semen quality, seminal characteristics and sperm parameters were evaluated in the
whole population. A statistically significant positive association was found between seminal holoTC,
CBL, and total sperm motility, concentration and total number, as well as a negative correlation with
semen pH (Table 4). Conversely, no association was found between any parameter and holoTC and
CBL in both semen and serum.
Table 3. Seminal parameters: Seminal parameters of morbidly obese and lean subjects are reported as
mean ± SD for normally distributed and median (IQR) for not-normally distributed parameters and
analysed with the Mann–Whitney U test for comparison between obese and lean subjects. Significant p
values are indicated in italics.
Seminal Parameter Morbidly Obesen = 47
Lean
n = 21
p
Mann–Whitney U
Progressive Motility (%) 45.0 (31.0) 55.0 (19.5) 0.017
Total Motility (%) 52.0 (25.0) 65.0 (18.5) 0.004
Normal Morphology (%) 3.0 (5.0) 5.0 (6.0) 0.167
Vitality (%) 69.0 (29.0) 80.0 (6.0) 0.013
Total Sperm Number (millions) 34.5 (161.8) 220.0 (328.5) 0.001
Sperm Concentration(million/ml) 10.0 (52.6) 52.5 (75.0) 0.013
Volume (ml) 3.1 ± 1.7 4.2 ± 1.4 0.019
pH 7.6 ± 0.3 7.4 ± 0.2 0.001
Abstinence (days) 4.5 ± 3.8 3.8 ± 2.0 0.707
Table 4. Correlations between seminal holoTC or CBL and seminal parameters. r and p values of
Spearman’s correlation are indicated. The analysis was performed on the whole population.
Seminal
HoloTC
Seminal
CBL
Total Sperm Motility (%) r = 0.394p = 0.012
r = 0.345
p = 0.027
Total Sperm Number (millions) r = 0.401p = 0.009
r = 0.482
p = 0.001
Sperm Concentration (mil/ml) r = 0.343p = 0.028
r = 0.465
p = 0.002
pH r = −0.535p = 0.0001
r = −0.481
p = 0.001
When the whole cohort of morbidly obese and lean subjects were stratified in two classes of
holoTC concentrations, according to the median value of holoTC (118 pmol/L) derived from the seminal
distribution of the whole cohort, total sperm number and seminal volume were significantly higher
and pH significantly lower in those subjects with high seminal holoTC (Figure 3A–C). Similar results
were obtained for total sperm number and pH (Figure 3D,E) but not for semen volume (Figure 3F)
when subjects were stratified according to the median seminal CBL levels (1,069 pmol/L).
Nutrients 2019, 11, 1540 8 of 14
Nutrients 2019, 11, x FOR PEER REVIEW 8 of 15 
 8 
S
p
e
rm
n
u
m
b
e
r
(m
il
)
S
p
e
rm
n
u
m
b
e
r
(m
il
)
holoTC (pmol/L)      <118 >118 CBL (pmol/L)          <1069 >1069
p
H
p
H
V
o
lu
m
e
 (
m
l)
V
o
lu
m
e
 (
m
l)
8.00
7.75
7.50
7.25
7.00
6.75
8.00
7.75
7.50
7.25
7.00
6.75
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
p=0.047 p=0.030
p=0.004 p=0.014
p=0.027 p=0.786
A D
B E
C F
holoTC (pmol/L)   <118 >118 CBL (pmol/L)          <1069 >1069
holoTC (pmol/L)   <118 >118 CBL (pmol/L)          <1069 >1069
 203 
Figure 3. Seminal parameters stratified for seminal holoTC and CBL in the total population of obese 204 
and lean subjects. Data reported as box charts indicates sperm number (A,D), seminal pH (B,E) and 205 
volume (C,F) in all subjects stratified for low and high seminal holoTC (A-C) and CBL (D-F), 206 
respectively. Cut-off values were chosen as the median value of holoTC (118 pmol/L) and CBL (1069 207 
pmol/L) distribution in the whole population; p values calculated with Mann-Whitney U’s test. 208 
In both cohorts, CBL and holoTC concentrations were significantly higher in semen vs. serum 209 
samples (CBL: P<0.001, and holoTC: P<0.005, Table 2, Fig.2). Morbidly obese subjects presented 210 
significantly lower concentrations of both CBL (p=0.006) and holoTC (p=0.025) in semen compared 211 
to lean subjects (Tab.1, Fig.2), while the differences between the two cohorts reached a statistical 212 
significance in the serum for CBL only (p=0.012, Table 1, Fig.2). Not-statistically significant 213 
correlations were found between holoTC/CBL and BMI, weight, waist circumference (WC), sex 214 
Figure 3. Seminal parameters stratified for seminal holoTC and CBL in the total population of obese
and lean subjects. Data reported as bo charts indicates sperm number (A,B), seminal pH (C,D),
and volume (E,F) in all subjects stratified f r l and high seminal holoTC (A, ,E) and CBL (B,D,F),
respectively. Cut-off values were chosen as the median value of holoTC (118 pmol/L) and CBL (1,069
pmol/L) distribution in the whole population; p values were calculated with the Mann-Whitney U test.
Finally, in order to compare the sensitivity and specificity f seminal and serum holoTC and CBL
in predicting semen quality, a ROC analysis was performed. A statistically significant accuracy in
predicting sperm number and concentration was found for seminal holoTC and CBL (Figure 4A–D), but
not for serum value . Th c t-off values identifying the best combination of sensitivity and specificity
of the methods are indicated. These cut-off values were similar to the median values of holoTC and
CBL distribution in semen (see Figure 3).
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statistically significant differences between the two groups are shown in Table 5.
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Table 5. Stratification of the whole subject cohort according to seminal holoTC and CBL cut-off values
identified by ROC analysis. Data is reported as median (IQR) for each parameter when all subjects
were stratified in two groups according to the indicated cut-off values of seminal holoTC and CBL
identified by ROC analysis. Significant p values after the Mann–Whitney U test are indicated.
Seminal HoloTC Seminal CBL
≥85.7
(pmol/L)
<85.7
(pmol/L) p
≥958
(pmol/L)
<958
(pmol/L) p
BMI (Kg/m2) 40.1 (39.0) 42.6 (15.8) 0.120 30.8 (27.1) 43.2 (36.1) 0.005
WC (cm) 120.0 (83.5) 142.0 (58.0) 0.032 120.0 (67.5) 144.0 (81.8) 0.018
Total Motility (%) 60.0 (79.0) 52.0 (75.0]) 0.034 65 (61.0) 54.0 (75.0) 0.066
Total Sperm Number (millions) 166.5 (567.7) 30.8 (281.0) 0.001 162.4 (567.6) 41.6 (408.0) 0.018
Sperm Concentration (million/ml) 44.0 (306.0) 9.5 (70.0) 0.001 44.0 (178.1) 10.0 (213.0) 0.03
pH 7.4 (1.2) 7.8 (0.6) 0.0001 7.4 (1.2) 7.6 (0.8) 0.005
4. Discussion
We observed some interesting and novel findings in this study. In line with the higher holoTC and
CBL concentrations found in semen compared to serum in the whole population of subjects studied,
it is likely that CBL may concentrate from the circulation to the seminal compartment. The higher
concentrations found for holoTC and CBL in semen might support a role of CBL in controlling semen
quality. Accordingly, a recent review showed that CBL and antioxidant supplementation can improve
semen quality, in particular enhancing sperm count and motility [27].
Secondly, we found that seminal CBL and holoTC concentrations were significantly lower than
serum levels in morbidly obese compared to lean subjects. This suggests that alterations associated with
high grades of obesity may somehow affect the process of local concentration in the reproductive tract,
at least in the ejaculate, thus contributing to the reduced semen quality observed in morbidly obese
men [17–22]. Indeed, we found a significant positive correlation between seminal holoTC/CBL and
some seminal parameters, which lost statistical significance when serum holoTC/CBL concentrations
were considered. In particular, this was found for both holoTC and CBL and total sperm motility,
total number, concentration, and seminal pH. Conversely, a not-statistically significant correlation
with normal sperm morphology was evident. This finding indicates an active role of seminal B12 in
controlling semen quality at the post-testicular level, such as in the epididymis, where spermatozoa are
concentrated and acquire active motility [39], as well as in semen production, acting on the prostate
and seminal vesicles. Interestingly, alterations at the post-testicular level in the control of sperm
maturation have also been hypothesized to contribute to the reduced semen quality found in morbid
obesity [17–22]. The extreme obesity may affect sperm quality at a post-testicular level, which was
confirmed by the absence of any effect on the normal morphology parameter and conversely related to
testicular maturation as previously shown [19].
The correlation between morbid obesity and hypogonadism has been extensively
validated [17,18,40], and the high prevalence of hypogonadism in this type of obesity has been
further confirmed. However, in our study no significant correlations were found between seminal
holoTC or CBL and sex steroid hormones, and no influence of hypogonadism on CBL was evident,
suggesting that hypogonadism does not contribute to regulate holoTC and CBL concentrations.
The role of seminal CBL in the post-testicular control of semen quality was further suggested by
the significant difference observed in total sperm number and semen pH between subjects stratified
according to low and high holoTC and CBL. In particular, seminal holoTC, but not CBL concentrations,
significantly differentiated patients for semen volume, which was substantially lower in subjects with
low seminal holoTC. Interestingly, semen volume was one of the parameters strictly associated with
prostate and seminal vesicle functionality [41]. Finally, according to the higher level of accuracy
and best sensitivity/specificity associated with seminal holoTC evaluation compared to CBL, seminal
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holoTC turned out to be the best predictor of semen quality (sperm number and concentration),
suggesting that this parameter could be considered as a potential useful marker of patients’ fertility.
One of the limitations recognized in our study was the limited number of subjects enrolled.
Accordingly, our results should be considered as preliminary. However, the number of morbidly obese
subjects enrolled was in line with the other studies conducted on morbidly obese subjects recruited in
bariatric surgery programs [17,18,21,42–44]. To exclude that the difference in the number of subjects
in the two cohorts could somehow affect the difference observed in holoTC and CBL, we calculated
Cohen’s d values (Cd) for holoTC and CBL in semen and serum of the morbidly obese and lean groups.
The values obtained (moderate level: semen holoTC Cd = 0.70, serum holoTC Cd = 0.77; high level:
semen CBL Cd = 1.11, serum CBL Cd = 2.82) indicate that the small size of the groups was unlikely to
affect the results. Our sample selection has two key strengths compared to previous papers [16,19,26]:
a) absence of any recruitment bias – the morbidly obese subjects were not recruited in andrology
centres, thus this does not affect fertility conditions, and b) parallel measurements of both holoTC and
CBL concentrations in semen and serum of the same subjects.
5. Conclusions
In conclusion, our findings suggest that seminal rather than serum holoTC might represent a
good marker of semen quality in morbidly obese subjects, whereby, despite the normal serum levels,
low CBL and holoTC were found. Further studies investigating the local levels of holoTC on large
populations including mildly obese/overweight subjects and elucidating the mechanisms which could
affect semen quality are warranted.
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